These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7238044)

  • 41. Pituitary and gonadal function during the use of norgestrelestradiol vaginal rings.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1978 Sep; 18(3):201-11. PubMed ID: 720065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaginal progesterone for contraception.
    Victor A; Jackanicz TM; Johansson ED
    Fertil Steril; 1978 Dec; 30(6):631-5. PubMed ID: 729823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in physiologically free circulating estradiol and testosterone during exposure to levonorgestrel.
    Stumpf PG; Nakamura RM; Mishell DR
    J Clin Endocrinol Metab; 1981 Jan; 52(1):138-43. PubMed ID: 6778889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use.
    Belsey EM
    Contraception; 1988 Aug; 38(2):207-25. PubMed ID: 2971506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of progestin R 2323 released from vaginal rings on ovarian function.
    Johansson ED; Luukkainen T; Vartiainen E; Victor A
    Contraception; 1975 Sep; 12(3):299-307. PubMed ID: 1164848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first year of use.
    Ratsula K
    Contraception; 1987 Dec; 36(6):659-66. PubMed ID: 3128429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
    Cekan SZ; Jia M; Landgren BM; Diczfalusy E
    Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical studies with a low dose estrogen-progestogen combination.
    Sartoretto JN; Ortega-Recio JC; Moraes R; Filho FN
    Contraception; 1977 May; 15(5):563-70. PubMed ID: 880827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis.
    Ling WY; Wrixon W; Acorn T; Wilson E; Collins J
    Fertil Steril; 1983 Nov; 40(5):631-6. PubMed ID: 6628707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First year clinical experience with six levonorgestrel rods as subdermal contraception.
    Faundes A; Brache de Mejias V; Leon P; Robertson D; Alvarez F
    Contraception; 1979 Aug; 20(2):167-75. PubMed ID: 487818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.
    Nilsson S; Nygren KG; Johansson ED
    Am J Obstet Gynecol; 1977 Sep; 129(2):178-84. PubMed ID: 900181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The vaginal contraceptive pill.
    Coutinho EM
    Adv Contracept Deliv Syst; 1986 Feb; 2(1):30-6. PubMed ID: 12267727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora.
    Roy S; Wilkins J; Mishell DR
    Contraception; 1981 Oct; 24(4):481-91. PubMed ID: 6797788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women.
    Van Santen MR; Haspels AA
    Fertil Steril; 1985 Feb; 43(2):206-13. PubMed ID: 3881294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.